AusBiotech is Australia’s life sciences peak body. For almost 40 years, we have worked to support the growth of our more than 3,000 members as they advance breakthroughs in medical science and develop new innovations to help solve some of Australia’s and the world’s most complex health challenges.

With our unrivalled membership breadth, representing all stages of the health innovation ecosystem, and drawing on our unique national convening power, we advocate for the advancement of Australian life sciences and our members’ success as they research, translate, develop and commercialise new health technologies, while supporting knowledge sharing and collaboration to help our life sciences innovators thrive.  

AusBiotech represents the breadth of the innovative health product lifecycle, from research to discovery, translation to development, manufacturing and commercialisation.

The State Government of Victoria is proud to be the Host State Sponsor for AusBiotech 2025 and welcomes you to Victoria.

Victoria is home to world-class health technology companies and is a preferred location for many global leaders including CSL, Moderna, BioNTech, Illumina, Telix Pharmaceuticals and Pfizer. International companies partner with Victoria for its outstanding strengths in commercial product development, its cost-competitive environment for basic discovery, clinical and commercial research, and its strong collaborative networks and supportive government.

Victoria is a global leader in health technologies research and manufacturing, delivering a sector value add of $5.5 billion in 2022. Victoria’s research and development capabilities include:
• Infectious disease and diagnostics
• Digital health and patient monitoring
• Cancer
• Cell therapies and regenerative medicine
• Medical devices and diagnostics
• Neuroscience
• Paediatrics

Victoria’s health technologies ecosystem is supported by its skilled and multicultural talent pool, favourable regulatory and research and development environment, and world leading infrastructure - all backed by the Victorian Government’s long-term investment into the sector.

The Victorian Government has recognised health technologies as a priority industry sector for more than two decades and is committed to working with business to grow the research and innovation ecosystem. It has a well-established strategy to help companies become part of the global supply chain in knowledge creation, product development and commercialisation. Its global network of 23 international business offices is working with international companies to assist them to partner with Victoria to develop novel health technologies and services.

We would welcome the opportunity to talk with you further how we might provide you with insights and partner to assist you access the full range of capabilities and talent in Victoria.

For more information on how the Victorian Government can support your business, visit the following websites:

• Melbourne where Global companies can scale: global.vic.gov.au/scale-in-melbourne
- djsir.vic.gov.au/health-tech
• Invest Victoria: invest.vic.gov.au
• Made in Victoria: vic.gov.au/madeinvictoria
• Business Victoria: business.vic.gov.au
• Breakthrough Victoria: breakthroughvictoria.com
• Regional Development Victoria: rdv.vic.gov.au/victorias-regions
• LaunchVic: LaunchVic: Victoria's Startup Agency
• Medical Research: https://djsir.vic.gov.au/medical-research
• mRNA Victoria: https://djsir.vic.gov.au/priorities-and-initiatives/mrna
• Agriculture Victoria: agriculture.vic.gov.au/farm-management/agtech

Science is at the heart of everything we do. It drives the discoveries we make and the technologies we create.

We make a positive difference to millions of people’s lives every day. Our constant curiosity and specialist approach drive our partnerships and bring new ideas to life. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices - Merck is everywhere.

We trust in the talent and passion of our curious minds; that’s why we’re creating an environment where they can unleash their potential and meet their individual needs. We foster a culture where everyone feels welcome. Our work is fueled by our belief in science as a force for good. We work to enhance the human experience and create more joyful and sustainable ways to live.

Agriculture Victoria Services (AVS) is a Victorian Government enterprise that enables the commercialisation of agricultural innovation. In partnership with Agriculture Victoria Research (AVR), AVS facilitates access to advanced research capabilities, SmartFarms, and world-class infrastructure. Through the formation of strategic partnerships, IP management and research translation, AVS connects organisations with the scientific expertise and platforms required to deliver measurable impact, supporting collaborative innovation that drives economic performance, environmental sustainability, and benefits for Victorian agriculture and broader communities.

CSL is a leading global biotechnology company headquartered in Melbourne, Australia, with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For more information about CSL, visit www.CSL.com.

Sanofi is an R&D-driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.

McCloud Consulting Group (MCG) is a leading Australian Contract Research Organisation (CRO), bringing over 20 years of international expertise in biostatistics and data management to clinical trials across the Pharmaceutical, Biotech industries and Medtech industries.

Our Expertise

MCG provides world-class expertise in:
• Clinical Trial Design & Analysis – Crafting robust methodologies for clinical trials, audits, and patient registries.
• Advanced Statistical Consulting – Leveraging cutting-edge statistical techniques from diverse fields to enhance trial outcomes.
• Clinical Data Management – Implementing comprehensive data quality plans to ensure the integrity, security, and efficiency of clinical data—saving you time and money.

Our Legacy

Founded in 2010 by Dr. Philip McCloud, MCG unites a team of highly skilled professionals dedicated to delivering exceptional quality outcomes and personalised service. With extensive experience collaborating with global pharmaceutical and biotech companies, MCG has played a pivotal role in securing successful global approvals for drug products for new indications.
Global Expertise, Local Excellence
MCG works closely with international health authorities, assisting in the design of development programs and addressing regulatory queries during drug registration. Our biostatisticians have successfully guided projects from inception to approval, ensuring scientific rigor and regulatory compliance.

Why MCG?

Our dynamic team excels in collaborating with clinical and study teams worldwide, providing pragmatic, cost-effective, and scientifically sound solutions for clinical trial design and sample size determination. We balance scientific excellence with budgetary considerations, ensuring optimized trial outcomes.
As a world-class Biometrics CRO, MCG delivers its global expertise to clients in Australia, the Asia-Pacific region, and beyond.

Partner with MCG

Discover how MCG can enhance your statistical consulting and data management projects with expertise that drives success.

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere.

Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award for advancing the clinical research profession through strong site partnerships.

Clinibase is a technology-led clinical trial services company tackling three of the biggest challenges in research: recruitment, billing, and real-time data.

Spun out of Cardiobase - with over 30 years of healthcare technology expertise - Clinibase combines full-service recruitment with a powerful Clinical Trial Management System (CTMS) + eSource to deliver speed, transparency, and value.

Our recruitment specialists connect with participants through tailored campaigns and empathetic engagement, ensuring trials recruit on time. With over 50 trials supported and 3,000+ participants recruited, we know what it takes to find the “needle in a haystack” and keep participants engaged.

What sets our recruitment apart is our performance-based model: Sponsors only pay for screened and randomised participants. This alignment removes financial risk and builds trust.

Clinibase Pulse Sponsor Dashboard gives Sponsors and CROs real-time updates on recruitment.

The Clinibase CTMS and eSource simplifies data capture, billing, and compliance for sites. The result: less admin, more focus on patients.

Headquartered in Melbourne, Clinibase is proud to support Australian and New Zealand sites and global sponsors in advancing the future of clinical trials.

Clinibase: Recruiting on time, "no outcome no pay", with real-time data you can see and trust.

West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year.

Headquartered in Exton, Pennsylvania, West in its fiscal year 2024 generated $2.89 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.

All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.

360biolabs, a BioAgilytix company is Australia's most comprehensive bioanalytical lab, providing a comprehensive range of assay services for the development of new therapeutics, vaccines and diagnostics in a quality-assured environment. Located in Australia, the jurisdiction of choice for early phase clinical trials, we offer a diverse range of pharmacokinetic (PK) and pharmacodynamic (PD) endpoints including small molecule and large molecule PK, ADA, NAb, biomarkers (MSD, SIMOA, Luminex, ELISpot), molecular assays and virology, in a single laboratory for all your clinical trial requirements.

Our global BioAgilytix team, with laboratories located in San Diego, Boston, Durham and Hamburg (Germany), can support your program from discovery DMPK through to Phase 4 clinical trials. We offer seamless transfer of assays from Phase 1 in Australia to our global labs for Phase 2 support.

Our Quality Management Systems include internationally recognised accreditation (OECD GLP, GCLP, ISO/IEC17025) and our assay validation process and reporting are consistent with FDA and EMEA guidelines.

The 360biolabs executive management team has more than 50 years combined industry experience. Our team of highly experienced scientific and QA professionals ensures high-quality science, data integrity and regulatory compliance through all phases of clinical development. 360biolabs is a trusted partner to many top global pharmaceutical and biotech companies. Our relentless dedication to accuracy, timeliness and regulatory rigor enables your therapeutic innovations to reach patients faster.

Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.

We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share diverse insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.

Syneos Health is powered by an authentic, inclusive and high-performance culture that cares for colleagues, customers, patients, communities and the environment.

Learn more about how our expert team members can help accelerate your success. Visit syneoshealth.com.

Avance Clinical – Accelerating Biotech Innovation Globally
Avance Clinical is the leading Australian-owned Contract Research Organisation (CRO), trusted by biotechnology companies worldwide to deliver high-quality, efficient, and flexible clinical trial solutions. With more than 30 years of experience, Avance Clinical partners with biotech innovators from first-in-human studies through to pivotal trials, leveraging Australia’s globally recognised clinical trial environment to accelerate development and maximise value creation.
The Australian Advantage
Biotechs partnering with Avance Clinical benefit from Australia’s streamlined regulatory framework, including no IND requirement and rapid ethics approvals that enable study start-up within 5–6 weeks. In addition, companies can access up to a 43.5% R&D rebate on eligible expenditure, reducing overall costs.
With one of the largest portfolios of first-in-human and early phase trials in Australia, Avance Clinical helps clients move quickly while generating high-quality data accepted by the FDA, EMA, and other agencies. This proven capability enables confident, timely decisions at critical development milestones
Global Reach, Local Expertise
Avance Clinical’s operations extend beyond Australia to North America and Asia, offering biotechs a truly global pathway. Through the GlobalReady model, clients transition seamlessly from early-phase trials in Australia to multi-country studies, maintaining speed, consistency, and regulatory alignment. This approach de-risks expansion and ensures continuity across programs.
Comprehensive Services for Biotechs
Avance Clinical delivers an integrated suite of services bridging pre-clinical to clinical development:
• ClinicReady: Pre-clinical and translational consulting to guide biotechs confidently from the lab to first-in-human studies.
• Project Management: Dedicated leaders embedded with client teams to drive timelines, budgets, and milestones from early phase through Phase II–III.
• Medical and Scientific Affairs: Expert support for study design, regulatory pathways, and medical oversight.
• Biometrics: In-house data management, biostatistics, and pharmacokinetics ensuring regulatory-ready reporting.
• Safety and Pharmacovigilance: Comprehensive safety oversight, medical monitoring, and global reporting.
• Medical Writing: Protocols, investigator brochures, and regulatory submissions tailored to international standards and fundraising needs.
Innovation and Collaboration
Avance Clinical’s biotech-only model ensures agility and collaboration, combining therapeutic expertise, lean decision-making, and advanced technology. Flexible, customised solutions reduce risk, optimise timelines, and generate the data needed for licensing, partnerships, and investment milestones.
Partnering with Purpose
Avance Clinical’s mission is simple: accelerate biotech innovation so life-changing therapies reach patients faster. With hundreds of successful partnerships and one of the largest early-phase portfolios in Australia, Avance Clinical stands as a trusted partner in scientific progress - helping biotechs navigate complexity, secure investor confidence, and deliver breakthroughs to patients worldwide.
Get in contact with our team today
enquiries@avancecro.com | https://www.linkedin.com/company/avance-clinical | https://www.avancecro.com/

At Smartways, we are proud to be the largest and fastest-growing dedicated healthcare logistics network across ANZ. With 40+ strategically located hubs and a fleet of over 350 trained drivers, we provide unmatched reach, servicing every capital city, regional centre and country location daily. Operating 24/7, 365 days a year, we specialise in critical, time-sensitive transport for the healthcare community including Medtech, Clinical Trials, Pharmaceuticals, Biotechnology, Life Sciences and Radiopharm.

Our expertise spans urgent Patient on Table and Trauma deliveries, direct drives, next-flight and same-day services, ensuring precision, reliability and speed where patient outcomes depend on it. Every hospital across the region is supported daily through a logistics network purpose-built for healthcare.

Beyond medical devices, we support clinical research, radio-nuclear and biotechnology supply chains. From first-in-human trial samples to high-value biologics, we safeguard shipments with validated temperature-controlled packaging, continuous monitoring and strict chain-of-custody protocols. We also provide trial site support, kit-room management and high-touch services for operating theatres and research facilities.

Technology drives our operations, with 95% of orders processed online or via system integrations, delivering automation, transparency and compliance across the supply chain. This ensures life-critical materials, from trial specimens to biologic therapies, arrive exactly where they are needed, when they are needed.

Smartways is also the first healthcare logistics provider in Australasia to operate 100% carbon neutral. We invest in domestic and international projects to offset emissions, covering all costs so sustainability never competes with affordability.

Our mission is to improve patient outcomes and enable innovation across healthcare by delivering excellence in clinical trials, life sciences, biotechnology, pharmaceuticals and medical devices—one shipment at a time.

At Cytiva, we envision a world in which access to life-changing therapies transforms human health. With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery.
We supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. Visit cytiva.com to learn more.

Southern Clinical Development Consulting: Your Partner for Clinical Success in Australia
At Southern Clinical Development Consulting (Southern CDC), we are your strategic partner in navigating Australia's world-class clinical trial landscape. Our mission is to accelerate your therapeutic pipeline, delivering new treatments to patients faster and more efficiently.
Specialising in high-demand therapeutic areas including oncology, immunology, and neurology, our expert team provides comprehensive, end-to-end trial management. From robust protocol development and streamlined regulatory submissions to proactive site management, we tailor every solution to meet your unique asset and timeline.
We unlock the full potential of the Australian advantage for our partners. Leverage our deep local expertise to navigate the streamlined ethics and TGA regulatory pathways and maximise your investment through the attractive R&D Tax Incentive program. By connecting you with world-class research sites and diverse patient populations, we position your trial for rapid recruitment and success.
More than a service provider, we act as a seamless extension of your team, providing the proactive oversight and strategic insights essential for confident decision-making. Let’s connect at AusBio 2025 to discuss how we can advance your program in Australia.

Aurora Biosynthetics is an advanced pharmaceuticals manufacturer based in Sydney, New South Wales, focused on enabling the development and production of RNA-based therapeutics and vaccines. The company is the exclusive operator of a purpose-built, government-funded facility designed to capture the growing demand for GMP RNA manufacturing capacity.

With over A$100 million in capital investment from the NSW State Government, Aurora operates Australia’s first sovereign RNA-focused CDMO. The unique facility offers end-to-end GMP manufacturing capabilities for plasmid DNA (pDNA), messenger RNA (mRNA), lipid nanoparticle (LNP) formulation, and fill/finish all within a single integrated site.

This consolidated infrastructure eliminates the need for multi-vendor coordination, reducing complexity, risk, and time-to-clinic for RNA developers.

Aurora’s platform is designed to support programs from preclinical through to commercial scale, with a focus on quality, regulatory compliance, and operational efficiency.

The company has secured a US$10 million anchor customer, with a pipeline of government-sponsored and commercial clients. Aurora’s operations are led by a team with deep RNA expertise and a strong understanding of the technical and logistical challenges faced by therapeutic developers.

Positioned at the intersection of sovereign capability and global demand, Aurora Biosynthetics provides a critical manufacturing solution for the growing RNA sector. Its integrated model, government backing, and technical depth make it a strategic partner for biotech and pharmaceutical companies seeking reliable, scalable, and compliant RNA manufacturing services.

For more than 50 years, La Trobe University has been transforming people and societies. The University works collaboratively across disciplines and with partners to develop fresh ways of thinking and conducting research – constantly seeking new ways to engage with and better serve its partners and communities, to build relationships and develop solutions for the issues facing society. Along with holding its top 300 ranking in Times Higher Education’s World University Rankings 2025, La Trobe earned the prestigious ‘Most Improved – Oceania Award’ in the QS World University Rankings 2025, rising 183 places over the past five years to claim its new spot at 217 of the 1,500 universities evaluated.

Magellan Stem Cells is a leading private Australian biotechnology company and a global leader in the research, development and manufacture of stem cells with a focus on conditions of unmet clinical need.

As one of Australia’s few TGA-licensed, GMP-certified CDMOs for cell therapies, we have built a strong reputation in mesenchymal stem cell (MSC) manufacturing, supported by Phase 3-ready facilities and robust GMP infrastructure. Our specialist knowledge in MSCs forms the foundation of a broader capability that extends to iPSCs, NK cells, CAR-T, exosomes, and other advanced cell types — making us the ideal partner from concept to commercialization.

The University of Melbourne: excellence in global research and education.
As a place of discovery and enquiry, the University of Melbourne’s purpose is to benefit society through the transformative impact of education and research. Established in 1853, the University of Melbourne is one of Australia’s oldest universities. With state-of-the-art facilities and a commitment to interdisciplinary collaboration, the University continues to be a driving force in shaping the future through impactful research.
The University is embedded within world-class research and innovation precincts, and actively engages with partners to help address major social, economic, health and environmental challenges. Our researchers work together with government, industry, the community and specialist research institutes to translate their discoveries. These partnerships enable advancements in sustainability, global resilience and health, as well as supporting economic and social empowerment.
With over 100 research centres and institutes, the University of Melbourne brings world-class expertise to solving today’s challenges, delivering education and research that are global in reach, ambition and impact. Our researchers are continuing to expand the boundaries of knowledge for the benefit of society, from using genomics to transform our national standard of cancer care to preserving Indigenous cultural materials and heritage
Bio21 Molecular Science and Biotechnology Institute (Bio21 Institute) is a flagship University of Melbourne interdisciplinary institute focused on molecular life sciences. Bio21 hosts more than 800 members with membership from all of the STEMM faculties of the University. Bio21 hosts some of the biggest and most successful platforms of scientific equipment in the nation including nuclear magnetic resonance, X-ray crystallography, mass spectrometry and cryo electron microscopy. It is also well known for its embedded industry tenant model that capitalises on the discoveries made at the University and its partners in the Melbourne Biomedical Precinct. Our current industry tenants include CSL, Aculeus Therapeutics, Alterity Therapeutics, Cyclotek, Gertrude Biomedical, Melbridge Therapeutics, Qubigen, Rhythm Biosciences, SYNtheses BioVentures, SYNthesis Research, Therapeutic Innovation Australia and Thermo Fisher Scientific. The core mission of the Bio21 Institute is to seek to improve human health and the environment through innovation in biotechnology and related areas, driven by collaborative research and dynamic interactions with industry.

Novartis is improving the lives of more than 2.5 million patients across Australia and New Zealand through our medicines. By partnering with the healthcare system we are working for patients to address their needs, and we are committed to accelerating patient access to life saving treatments and associated healthcare.

We are reimagining medicine by using innovative science and technology to address challenging healthcare issues and our rich research pipeline has 50+ ongoing Phase III programs. We are transforming how clinical trials are run to increase patients’ access to our industry-leading clinical trials footprint in Australia.

We continue to work on improving our environment for diversity, equity and inclusion and being a family friendly employer. Every day our inspired, curious, unbossed, and integrity-driven culture unites our people and encourages leadership at every level.

Radium Capital is Australia’s leading provider of R&D finance, proudly supporting the growth of the nation’s biotech, medtech and health innovation sectors.

Since 2017, we’ve deployed more than $950 million in non-dilutive funding to over 1,000 Australian innovators, helping life sciences companies launch, scale and commercialise faster.

We provide early access to the R&D Tax Incentive refund through Radium Advances — enabling eligible businesses to reinvest in growth, smooth cash flow, attract additional funding, and reduce capital outlay. Advances can be used as one-off injections or used strategically throughout the year and are designed to complement other forms of capital.

Radium Capital was created by entrepreneurs for entrepreneurs, with the goal of giving R&D-focused companies the right funding at the right time. We’re proud to play a role in strengthening Australia’s innovation ecosystem by providing capital, connections and trusted advice to help move ideas to impact.
We work with companies across the full spectrum of innovation, from startups to ASX-listed firms, and across sectors, including biotech, medtech, digital health and health innovation.

If you are eligible for the R&DTI refund, you can apply for a Radium Advance – visit radimcapital.com.au to learn about how we can help you achieve your goals, sooner.

Telix is a global, commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Their focus is on urologic, neurologic, musculoskeletal and hematologic oncology, and their pipeline is underpinned by a strong global supply, manufacturing and distribution network.
Telix has received global regulatory approvals in Australia, Brazil, Canada, the United Kingdom, the United States (U.S.) and a number of European Economic Area member states for its first generation prostate cancer imaging agent, and its second generation prostate imaging agent is approved in the U.S. Telix has more than 30 clinical trials underway worldwide (including partnered investigator-initiated trials).
Telix utilises the power of targeted radiopharmaceuticals to diagnose, treat, and manage cancers and rare diseases.
Telix’s radiopharmaceuticals are designed to deliver focused doses of radiation with precision targeting via systemic injection. They do this by attaching a radioactive isotope (‘payload’) to a targeting agent, such as a small molecule or antibody, which has an affinity for biomarkers found on the surface of cancerous or diseased cells.
The drug is delivered intravenously and seeks out cancerous cells wherever they are in the body, including where the cancer has spread. It then binds only to those cells, concentrating radiation at the tumour sites and limiting off-target tissue exposure. This is different from traditional radiation therapy, which is typically only delivered to where an identified tumour is located.
Importantly, Telix pairs each therapeutic with a diagnostic imaging agent. This underpins the “theranostic” approach where two conjugates are used to target the same receptor on the cancer cell – one for detection, localisation and/or staging and the other for selective destruction of target cancer cells. Used in tandem, they help plan and deliver treatment while also enabling the response as well as any progression of disease to be monitored.